LCM
XENE icon

Legato Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Legato Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27M Buy
54,226
+17,585
+48% +$976K 0.27% 109
2026
Q1 		$2.13M Sell
36,641
-397
-1% -$18.3K 0.19% 162
2025
Q4 		$1.66M Buy
37,038
+22,829
+161% +$959K 0.14% 222
2025
Q3 		$570K Buy
14,209
+4,587
+48% +$162K 0.06% 427
2025
Q2 		$301K Hold
9,622
– – 0.04% 498
2025
Q1 		$323K Buy
+9,622
New +$365K 0.04% 478
2024
Q2 		– Sell
-16,085
Closed -$692K – 630
2024
Q1 		$692K Buy
16,085
+4,248
+36% +$195K 0.08% 361
2023
Q4 		$545K Buy
11,837
+155
+1% +$5.48K 0.07% 398
2023
Q3 		$399K Sell
11,682
-628
-5% -$23.5K 0.06% 441
2023
Q2 		$474K Buy
+12,310
New +$489K 0.06% 432

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Legato Capital Management's XENE Position: Q2 2026 in Review

Legato Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 48% in Q2 2026, buying an estimated $976K and bringing the position to 54,226 shares worth $3.27M. The position accounts for 0.27% of the portfolio, ranked #109.

Legato Capital Management first reported a position in XENE in Q2 2023 and has held it in 10 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Legato Capital Management held 54,226 shares of Xenon Pharmaceuticals worth $3.27M as of Q2 2026.
  • Legato Capital Management bought 17,585 Xenon Pharmaceuticals shares in Q2 2026, an estimated $976K.
  • Xenon Pharmaceuticals made up 0.27% of Legato Capital Management's portfolio in Q2 2026, its #109 holding.
  • Legato Capital Management first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 10 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.